经鼻高流量氧疗用于钝性胸部创伤轻中度急性呼吸衰竭:一项探索性描述性研究
本研究为回顾性分析,纳入2021年1月至2022年12月急诊医学科收治的157例钝性胸部创伤合并轻中度低氧性急性呼吸衰竭患者,其中经鼻高流量氧疗组72例、无创通气组85例。主要终点治疗失败率在经鼻高流量氧疗组为11.1%,无创通气组为16.5%,风险差5.36%(95%CI -5.94~16.10%;P=0.366),无显著差异。经鼻高流量氧疗组治疗不耐受发生率显著低于无创通气组(1.4% vs 9.4%,95%CI 0.40~16.18;P=0.039)。经鼻高流量氧疗失败的危险因素包括慢性呼吸系统疾病、简明损伤定级(胸部)≥3分、急性生理与慢性健康评分Ⅱ≥15分、治疗1小时时动脉血氧分压/吸入氧浓度≤200及治疗1小时时呼吸频率≥32次/分。
要点
- 钝性胸部创伤合并轻中度低氧性急性呼吸衰竭患者中,经鼻高流量氧疗组治疗失败率11.1%,无创通气组16.5%,风险差5.36%(95%CI -5.94~16.10%;P=0.366),无显著差异。
- 经鼻高流量氧疗组治疗不耐受发生率1.4%,显著低于无创通气组的9.4%(95%CI 0.40~16.18;P=0.039)。
- 经鼻高流量氧疗组治疗失败最常见原因为呼吸窘迫加重,无创通气组最常见原因为治疗不耐受。
- 经鼻高流量氧疗失败的危险因素包括慢性呼吸系统疾病、简明损伤定级(胸部)≥3分、急性生理与慢性健康评分Ⅱ≥15分、治疗1小时时动脉血氧分压/吸入氧浓度≤200及呼吸频率≥32次/分。
适用人群与场景
- 2021年1月至2022年12月急诊医学科收治的钝性胸部创伤合并轻中度低氧性急性呼吸衰竭患者,共157例(经鼻高流量氧疗组72例,无创通气组85例)。
研究设计与关键结果
- 回顾性分析纳入157例钝性胸部创伤合并轻中度低氧性急性呼吸衰竭患者,经鼻高流量氧疗组72例,无创通气组85例。
- 主要终点治疗失败率:经鼻高流量氧疗组11.1%,无创通气组16.5%,风险差5.36%(95%CI -5.94~16.10%;P=0.366),无显著差异。
- 经鼻高流量氧疗组治疗失败最常见原因为呼吸窘迫加重,无创通气组最常见原因为治疗不耐受。
- 治疗不耐受发生率经鼻高流量氧疗组1.4%,显著低于无创通气组9.4%(95%CI 0.40~16.18;P=0.039)。
- 单因素logistic回归分析显示,经鼻高流量氧疗失败的危险因素包括慢性呼吸系统疾病、简明损伤定级(胸部)≥3分、急性生理与慢性健康评分Ⅱ≥15分、治疗1小时时动脉血氧分压/吸入氧浓度≤200及治疗1小时时呼吸频率≥32次/分。
证据类型、等级与局限
- 证据类型:回顾性分析(探索性描述性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在钝性胸部创伤合并轻中度低氧性急性呼吸衰竭患者中,使用经鼻高流量氧疗与无创通气相比未导致更高的治疗失败率,且经鼻高流量氧疗提供更好的舒适度和耐受性,作者认为其可能是此类患者有前景的新型呼吸支持疗法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The use of high-flow nasal cannula (HFNC) oxygen therapy is gaining popularity for the treatment of acute respiratory failure (ARF). However, limited evidence exists regarding the effectiveness of HFNC for hypoxemic ARF in patients with blunt chest trauma (BCT).
METHODS: This retrospective analysis focused on BCT patients with mild-moderate hypoxemic ARF who were treated with either HFNC or non-invasive ventilation (NIV) in the emergency medicine department from January 2021 to December 2022. The primary endpoint was treatment failure, defined as either invasive ventilation, or a switch to the other study treatment (NIV for patients in the NFNC group, and vice-versa).
RESULTS: A total of 157 patients with BCT (72 in the HFNC group and 85 in the NIV group) were included in this study. The treatment failure rate in the HFNC group was 11.1% and 16.5% in the NIV group - risk difference of 5.36% (95% CI, -5.94-16.10%; P = 0.366). The most common cause of failure in the HFNC group was aggravation of respiratory distress. While in the NIV group, the most common reason for failure was treatment intolerance. Treatment intolerance in the HFNC group was significantly lower than that in the NIV group (1.4% vs 9.4%, 95% CI 0.40-16.18; P = 0.039). Univariate logistic regression analysis showed that chronic respiratory disease, abbreviated injury scale score (chest) (≥3), Acute Physiology and Chronic Health Evaluation II score (≥15), partial arterial oxygen tension /fraction of inspired oxygen (≤200) at 1 h of treatment and respiratory rate (≥32 /min) at 1 h of treatment were risk factors associated with HFNC failure.
CONCLUSION: In BCT patients with mild-moderate hypoxemic ARF, the usage of HFNC did not lead to higher rate of treatment failure when compared to NIV. HFNC was found to offer better comfort and tolerance than NIV, suggesting it may be a promising new respiratory support therapy for BCT patients with mild-moderate ARF.
参考来源
- Zhu Q, Tan D, Wang H, et al. High-flow nasal cannula oxygen therapy for mild-moderate acute respiratory failure in patients with blunt chest trauma: An exploratory descriptive study. Am J Emerg Med. 2024. PMID: 38981159. doi:10.1016/j.ajem.2024.07.002
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。